Centene Corporation (0HVB.L)
USD 59.81
(-0.08%)
USD 59.81
(-0.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -463 Million USD | 50.97% |
| 2022 | 4.05 Billion USD | -7.23% |
| 2021 | 3.95 Billion USD | -57.95% |
| 2020 | 4.76 Billion USD | -81.55% |
| 2019 | 2.83 Billion USD | -3.69% |
| 2018 | 2.2 Billion USD | -143.73% |
| 2017 | 1.75 Billion USD | 30.89% |
| 2016 | 1.65 Billion USD | -603.13% |
| 2015 | 851 Million USD | -190.91% |
| 2014 | -22 Million USD | 18.52% |
| 2013 | -27 Million USD | 20.59% |
| 2012 | -34 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -134 Million USD | 275.29% |
| 2024 Q2 | -183 Million USD | -100.36% |
| 2024 Q3 | 1.41 Billion USD | 20242.86% |
| 2023 Q3 | -665 Million USD | -468.38% |
| 2023 Q1 | -150 Million USD | 72.01% |
| 2023 FY | - USD | 50.97% |
| 2023 Q4 | -213 Million USD | 67.97% |
| 2023 Q2 | -117 Million USD | 22.0% |
| 2022 Q2 | -1.49 Billion USD | -473.95% |
| 2022 Q1 | -261 Million USD | -1066.67% |
| 2022 Q3 | 8 Million USD | 100.53% |
| 2022 FY | - USD | -7.23% |
| 2022 Q4 | -536 Million USD | -6800.0% |
| 2021 Q3 | 10 Million USD | 100.67% |
| 2021 Q4 | 27 Million USD | 170.0% |
| 2021 FY | - USD | -57.95% |
| 2021 Q1 | -316 Million USD | -36.8% |
| 2021 Q2 | -1.5 Billion USD | -375.32% |
| 2020 Q2 | -253 Million USD | 48.05% |
| 2020 Q1 | -487 Million USD | -204.38% |
| 2020 Q4 | -231 Million USD | 4.55% |
| 2020 Q3 | -242 Million USD | 4.35% |
| 2020 FY | - USD | -81.55% |
| 2019 Q2 | -119 Million USD | -5.31% |
| 2019 Q3 | -394 Million USD | -231.09% |
| 2019 FY | - USD | -3.69% |
| 2019 Q1 | -113 Million USD | -15.31% |
| 2019 Q4 | -160 Million USD | 59.39% |
| 2018 Q2 | -80 Million USD | 8.05% |
| 2018 Q1 | -87 Million USD | -625.0% |
| 2018 Q4 | -98 Million USD | 80.12% |
| 2018 FY | - USD | -143.73% |
| 2018 Q3 | -493 Million USD | -516.25% |
| 2017 Q4 | -12 Million USD | 82.35% |
| 2017 Q3 | -68 Million USD | -11.48% |
| 2017 Q2 | -61 Million USD | 42.99% |
| 2017 Q1 | -107 Million USD | 35.93% |
| 2017 FY | - USD | 30.89% |
| 2016 Q4 | -167 Million USD | -145.59% |
| 2016 FY | - USD | -603.13% |
| 2016 Q3 | -68 Million USD | 10.53% |
| 2016 Q2 | -76 Million USD | 65.92% |
| 2016 Q1 | -223 Million USD | -2130.0% |
| 2015 Q2 | -13 Million USD | -18.18% |
| 2015 FY | - USD | -190.91% |
| 2015 Q1 | -11 Million USD | -450.0% |
| 2015 Q4 | -10 Million USD | 66.67% |
| 2015 Q3 | -30 Million USD | -130.77% |
| 2014 Q2 | -8 Million USD | -33.33% |
| 2014 Q4 | -2 Million USD | 66.67% |
| 2014 Q3 | -6 Million USD | 25.0% |
| 2014 FY | - USD | 18.52% |
| 2014 Q1 | -6 Million USD | 20.66% |
| 2013 Q1 | -6.53 Million USD | -2035.29% |
| 2013 FY | - USD | 20.59% |
| 2013 Q3 | -6.14 Million USD | 6.34% |
| 2013 Q4 | -7.56 Million USD | -23.08% |
| 2013 Q2 | -6.56 Million USD | -0.4% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | -306 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Phreesia, Inc. | -102.94 Million USD | -349.755% |
| Accuray Incorporated | 9 Million USD | 5239.305% |
| Align Technology, Inc. | 799.03 Million USD | 157.945% |
| Elevance Health Inc. | 10.49 Billion USD | 104.414% |
| AxoGen, Inc. | -13.32 Million USD | -3373.89% |
| Boston Scientific Corporation | 3.61 Billion USD | 112.815% |
| CVS Health Corporation | 18.17 Billion USD | 102.547% |
| Cardinal Health, Inc. | 1.97 Billion USD | 123.407% |
| DaVita Inc. | 2.34 Billion USD | 119.732% |
| HCA Healthcare, Inc. | 12.72 Billion USD | 103.64% |
| Hologic, Inc. | 1.29 Billion USD | 135.72% |
| Humana Inc. | -561 Million USD | 17.469% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 138.024% |
| Laboratory Corporation of America Holdings | 1.34 Billion USD | 134.312% |
| Masimo Corporation | 236.7 Million USD | 295.606% |
| McKesson Corporation | 4.66 Billion USD | 109.921% |
| Patterson Companies, Inc. | 374.75 Million USD | 223.547% |
| Quest Diagnostics Incorporated | 1.73 Billion USD | 126.732% |
| ResMed Inc. | 1.6 Billion USD | 128.932% |
| Henry Schein, Inc. | 943 Million USD | 149.099% |
| Teladoc Health, Inc. | 153.99 Million USD | 400.655% |
| Universal Health Services, Inc. | 1.74 Billion USD | 126.557% |
| Veeva Systems Inc. | 429.33 Million USD | 207.841% |
| Baxter International Inc. | 2.77 Billion USD | 116.679% |
| Becton, Dickinson and Company | 4.27 Billion USD | 110.83% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 119.339% |
| Danaher Corporation | 7.49 Billion USD | 106.174% |
| Stryker Corporation | 5.16 Billion USD | 108.973% |
| Medtronic plc | 9.05 Billion USD | 105.113% |